Evolution of the incidence of inflammatory bowel disease in Southern Spain

Benallal, Dina Chaaro; Veloz, María Fernanda Guerra; Argüelles-Arias, Federico; Benítez, José Manuel; Amarillo, Raúl Perea; Iglesias, Eva; Laria, Luisa Castro; García, Valle; Pérez, Manuel Jesús Soriano; Vilches, Ángel; Álvarez, Ángel Caunedo; Romero‐Gómez, Manuel

doi:10.17235/reed.2017.4739/2016

Cited by 7 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Even among the countries/regions with increasing incidence, the collective data indicate that this might be particular to Western nations catching up to a common incidence. For example, in southern Spain, the incidence of IBD increased from 3.5 per 100,000 in 1995–2000 to 14.7 per 100,000 in 2001–2014, which is still lower than most reported incidence values in the Western world, for which the mean incidence for the period 2001–2014 was 1.4 times higher (19.77 per 100,000) 41 . Future studies will demonstrate whether incidence will eventually level off in most countries/regions in the Western world; such stabilization in incidence will denote the end of the second epidemiological stage.…”

Section: Stage Two: Acceleration In Incidencementioning

confidence: 70%

“…By contrast, some studies have found that IBD incidence in children 38 , including IBD of very early onset 39 , has increased in the Western world over the past two decades. Furthermore, incidence continues to increase in certain countries including New Zealand 40 and some countries/regions in Europe, such as Spain 41 and Denmark 42 . Even among the countries/regions with increasing incidence, the collective data indicate that this might be particular to Western nations catching up to a common incidence.…”

Section: Stage Two: Acceleration In Incidencementioning

confidence: 99%

See 1 more Smart Citation

The four epidemiological stages in the global evolution of inflammatory bowel disease

Kaplan

Windsor

2020

Nat Rev Gastroenterol Hepatol

573

428

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a global disease; its evolution can be stratified into four epidemiological stages: Emergence, Acceleration in Incidence, Compounding Prevalence and Prevalence Equilibrium. In 2020, developing countries are in the Emergence stage, newly industrialized countries are in the Acceleration in Incidence stage, and Western regions are in the Compounding Prevalence stage. Western regions will eventually transition to the Prevalence Equilibrium stage, in which the accelerating prevalence levels off as the IBD population ages and possibly as a result of an unexpected rise in mortality during the COVID-19 pandemic. Mitigating the global burden of IBD will require concerted efforts in disease prevention and health-care delivery innovations that respond to changing demographics of the global IBD population. In this Perspective, we summarize the global epidemiology of IBD and use these data to stratify disease evolution into four epidemiological stages.

show abstract

Section: Stage Two: Acceleration In Incidencementioning

confidence: 70%

Section: Stage Two: Acceleration In Incidencementioning

confidence: 99%

The four epidemiological stages in the global evolution of inflammatory bowel disease

Kaplan

Windsor

2020

Nat Rev Gastroenterol Hepatol

573

428

View full text Add to dashboard Cite

show abstract

“…Inflammatory bowel diseases (IBDs) are a group of auto-immune pathologies, with Crohn's disease (CD) and ulcerative colitis (UC) among the most well-known. They are both of recurrent clinical course and show a higher incidence in developed countries [1,2].…”

Section: Introductionmentioning

confidence: 99%

“…Besides, during the second half of the 21st century, the incidence of these diseases has risen in developed countries, reaching numbers of 6–10/100,000 inhabitants/year in Europe [ 8 ]. These figures apply to Spain, both in terms of the increasing number of cases and in the cardinal differences, and are evident in the regions of Córdoba and Seville [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

Probiotics as a Coadjuvant Factor in Active or Quiescent Inflammatory Bowel Disease of Adults—A Meta-Analytical Study

et al. 2020

View full text Add to dashboard Cite

(1) Background: Inflammatory bowel diseases are pathologies of unknown etiology and auto-immune pathogenia. The use of probiotics is studied in order to increase the arsenal of treatments. The aim was to assess the efficacy of the probiotics in these diseases in the active or quiescent phases; (2) Methods: A systematic review with meta-analysis was performed by an exhaustive bibliographic search in Medline, Cinahl, Embase, Scopus, Web of Science, and Cochrane Library. The inclusion criteria were studies of more than 10 years, English/Spanish, clinical trials, and involving human beings. Relative risk was used to compare efficacy, which was meta-analyzed using a fixed effects model. Heterogeneity was evaluated with the Higgins I2 test; (3) Results: Nineteen studies were included in the systematic review and 17 in the meta-analysis, with a total of 1537 patients (nexperimental group = 762; nplacebo group = 775). There are significant remission differences in ulcerative colitis (relative risk (RR) = 0.81; 95% CI = 0.72–0.91; I2 = 32%; p = 0.16). However, no significant differences were found in the use of probiotics for the prevention of ulcerative colitis, and for the remission of Crohn’s disease; (4) Conclusions: There are data showing an additional beneficial effect of probiotics on active ulcerative colitis. More and better studies are needed which assess its possible therapeutic efficacy for quiescent ulcerative colitis and for Crohn’s disease.

show abstract

“…The studies conducted on the incidence of IBD in Spain are summarized in Supplementary Table 1. 17,19–45 Most of these studies were carried out more than a decade ago in selected areas and included a small number of patients. Differences in IBD incidence between regions have been reported, with variability between urban and rural centers and between inland and coastal areas even within a single region.…”

Section: Introductionmentioning

confidence: 99%

EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain

Chaparro¹,

Acosta

Benítez

et al. 2019

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Inflammatory bowel disease (IBD) is associated with a considerable burden to the patient and society. However, current data on IBD incidence and burden are limited because of the paucity of nationwide epidemiological studies, heterogeneous designs, and a low number of participating centers and sample size. The EpidemIBD study is a large-scale investigation to provide an accurate assessment of the incidence of IBD in Spain, as well as treatment patterns and outcomes. Methods: This multicenter, population-based incidence cohort study included patients aged >18 years with IBD (Crohn’s disease, ulcerative colitis, or unclassified IBD) diagnosed during 2017 in 108 hospitals in Spain, covering 50% of the Spanish population. Each participating patient will attend 10 clinic visits during 5 years of follow up. Demographic data, IBD characteristics and family history, complications, treatments, surgeries, and hospital admissions will be recorded. Results: The EpidemIBD study is the first large-scale nationwide study to investigate the incidence of IBD in Spain. Enrollment is now completed and 3627 patients are currently being followed up. Conclusions: The study has been designed to overcome many of the limitations of previous European studies into IBD incidence by prospectively recruiting a large number of patients from all regions of Spain. In addition to epidemiological information about the burden of IBD, the 5-year follow-up period will also provide information on treatment patterns, and the natural history and financial burden of IBD.

show abstract

Evolution of the incidence of inflammatory bowel disease in Southern Spain

Abstract: The incidence of inflammatory bowel disease in Southern Spain has doubled in the last decade and is similar to that of the rest of the country and Europe.

Cited by 7 publications

References 15 publications

The four epidemiological stages in the global evolution of inflammatory bowel disease

The four epidemiological stages in the global evolution of inflammatory bowel disease

Probiotics as a Coadjuvant Factor in Active or Quiescent Inflammatory Bowel Disease of Adults—A Meta-Analytical Study

EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain

Contact Info

Product

Resources

About